AbbVie agreed to sell Humira through the government’s TrumpRx direct-to-consumer platform at a reported 86% discount as the administration works to manage tariff threats and broader pricing policy. According to the reporting, Humira would be priced at about $950 through TrumpRx for uninsured patients, versus list prices that can exceed $6,900. AbbVie is also offering Synthroid and certain ophthalmology products (Combigan and Alphagan) on the same platform. The structure ties TrumpRx participation to tariff and potential price-mandate exemptions, with discount pricing applying mainly to patients without insurance or plans that do not cover the relevant medicines. TrumpRx launched earlier than expected after delays. For commercial strategy, the key near-term variable will be how quickly payers and manufacturers re-route pricing dynamics under the policy—especially once tariff timing and onshoring conditions are fully realized.